Elicio Therapeutics (ELTX) Current Deferred Revenue (2020 - 2025)
Elicio Therapeutics' (ELTX) quarterly Current Deferred Revenue came in at $680000.0 in Q1 2025, up 8.45% YoY from $627000.0 in Q1 2024, and down 41.83% on a QoQ basis from $1.2 million in Q4 2024.
Elicio Therapeutics (ELTX) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Elicio Therapeutics (ELTX) has 6 years of Current Deferred Revenue data on file, last reported at $680000.0 in Q1 2025.
- Quarterly Current Deferred Revenue rose 8.45% year-over-year to $680000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $680000.0 (up 8.45% YoY) and the FY2024 annual result came in at $1.2 million, up 68.44% from the prior year.
- Current Deferred Revenue declined to $680000.0 in Q1 2025, from $1.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $5.2 million in Q2 2021 to a low of $400000.0 in Q2 2024.
- A 5-year average of $1.9 million and a median of $1.3 million in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 82.78% — and 2024, when it jumped 68.44%.
- Tracing ELTX's Current Deferred Revenue over 5 years: stood at $2.3 million in 2021, then tumbled by 37.59% to $1.4 million in 2022, then tumbled by 51.67% to $694000.0 in 2023, then jumped by 68.44% to $1.2 million in 2024, then plunged by 41.83% to $680000.0 in 2025.
- The last three Current Deferred Revenue figures came in at $680000.0 (Q1 2025), $1.2 million (Q4 2024), and $400000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 680,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 627,000.00 |
| Dec 31, 2023 | 694,000.00 |
| Sep 30, 2023 | 1.66 Mn |
| Dec 31, 2022 | 1.44 Mn |
| Mar 31, 2022 | 653,000.00 |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 3.66 Mn |
| Jun 30, 2021 | 5.18 Mn |
| Mar 31, 2021 | 3.79 Mn |
| Dec 31, 2020 | 3.94 Mn |